3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
17
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
9
Neoplasm Metastasis
6
Prostatic Neoplasms
5
Melanoma
5
Lung Neoplasms
5
Solid Tumor
3
Pain, Postoperative
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Gastrointestinal Stromal Tumors
3
Colorectal Neoplasms
3
Anxiety Disorders
3
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Pain
2
Glioma
2
Colonic Neoplasms
2
Choledocholithiasis
2
Choledochal Cyst
2
Carcinoma
2
Advanced Solid Tumor
2
Advanced Malignancies
2
cMET-dysregulated Advanced Solid Tumors
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Interventions
Doxorubicin
25
Radiotherapy
15
Ifosfamide
14
Trabectedin
10
pazopanib
6
ribociclib
5
pembrolizumab
5
Specimen Handling
5
Gemcitabine
5
Biopsy
5
palbociclib
4
Magnetic Resonance Spectroscopy
4
Docetaxel
4
Chemotherapy, Adjuvant
4
selinexor
3
liposomal doxorubicin
3
eribulin
3
X-Rays
3
Vincristine
3
Radiation
3
Neoadjuvant Therapy
3
Imatinib Mesylate
3
Filgrastim
3
Etoposide
3
Cyclophosphamide
3
toripalimab
2
temsirolimus
2
romidepsin
2
pegfilgrastim
2
cixutumumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Liposarcoma
×
Midazolam
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled